Richmond Pharmacology is delighted to confirm our participation in BIO International Convention 2025 in Boston, the premier global event for biotechnology, attracting innovators and industry leaders from around the world.

With thousands of professionals expected to attend, this year’s convention will emphasize breakthroughs in therapeutic discovery, cutting-edge technologies, and global clinical collaboration.

Representing Richmond Pharmacology at BIO International Convention:

●    Dr. Jörg Täubel, Chief Executive Officer

●    Dr Lisa Campbell, Director of Regulatory Strategy

●    Stephen Wilkinson, Business Development Manager

●    Amina Senoussi, Key Account Executive

Our team is excited to connect with biotech innovators and trial sponsors to explore opportunities in:

●    Gene editing and RNA-based therapies

●    Rare and ultra-rare disease research

●    Innovative regulatory pathways

●    Bridging studies

●    Patient-centric clinical trial delivery

Whether you're advancing a ground breaking therapy or expanding into new markets, we invite you to meet us at Booth 765 in the Exhibit Hall to discover how Richmond Pharmacology can help achieve your clinical development objectives.

For meeting requests or collaboration inquiries, please contact:
📧 s.wilkinson@richmondpharmacology.com

 Learn more about the event

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

HFA 2025

17–20 May 2025
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
View event